ATHE News and Press, Alterity Therapeutics Limited From 04/06/22

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting PR Newswire The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO , ...

Alterity Therapeutics to Present at the 34th Annual Roth Conference PR Newswire MELBOURNE, Australia and SAN FRANCISCO , March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company d...

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease Study demonstrates reduction of α-synuclein aggregation and preservation of neurons PR Newswire ...

Appendix 4C - Q2 FY22 Quarterly Cash Flow Report PR Newswire Highlights: NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH4...

These Penny Stocks Climbed During Premarket, Here’s Why One of the best ways to stay ahead with penny stocks is to find the largest premarket gainers. While this is in no way the only strategy to use when trading penny stocks , it can be a major asset. Typically, premarket ga...

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's Composition of Matter Patent Covers More than 80 Novel Compounds PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, ...

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference PR Newswire MELBOURNE, Australia , Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated t...

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 PR Newswire MELBOURNE, Australia , Dec. 14, 2021 /PRNewswire/ -- Alterity Therapeutic...

The following slide deck was published by Alterity Therapeutics Limited in conjunction with this event. For further details see: Alterity Therapeutics (ATHE) AGM CEO Address 2021 - Slideshow

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company ...